Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000409605 | SCV000488613 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-05-05 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000588007 | SCV000694665 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2015-11-20 | criteria provided, single submitter | clinical testing | Variant summary: The variant of interest causes a frameshift/truncating mutation and is predicted to have a "disease-causing" outcome by mutation taster. The variant is absent from the large and broad cohorts of the NHLBI-ES and ExAC projects and, to our knowledge, has not been reported in HBOC spectrum patients either. In vivo/vitro studies to describe the functional impact of the variant have not been published at the time of scoring. Variants overlapping with the variant of interest e.g. c.3076A>T p.Lys1026X (ARUP, BIC), p.3075_3076 delinsTT p.Lys1025AsnTer (UMD, ClinVar) have been reported in HBOC patients indicating that the variant of interest is located in a mutation hotspot. The variant of interest shows evidence for pathogenicity: it is a frameshift/truncating mutation and is absent from controls (ESP, ExAC), it is located in a mutational hotspot. Therefore it was classified as a Likely Pathogenic. |